[Skip to Content]
[Skip to Content Landing]
Views 870
Citations 0
Comment & Response
September 11, 2018

Antiplatelet Therapy After Coronary Artery Bypass Grafting

Author Affiliations
  • 1Section of Cardiac Surgery, Yale University School of Medicine, New Haven, Connecticut
JAMA. 2018;320(10):1035-1036. doi:10.1001/jama.2018.10438

To the Editor The Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery (DACAB) trial provides needed insight into the utility of dual antiplatelet therapy (DAPT) with ticagrelor as the second agent in patients undergoing CABG.1 The current American Heart Association and American College of Cardiology (AHA/ACC) guideline is based on limited evidence and restricted to resumption of DAPT in patients who present with acute coronary syndrome. Consequently, intersurgeon variability in DAPT use is high with a relatively low rate of DAPT use.2